CRISPR-AD: Combinational Detection of Blood Protein and miRNA with Digital CRISPR-Based Assay Enable to Improve the Diagnostic Performance of Alzheimer’s Disease
Analytical Chemistry · 10.02.2026 · 98 (5) · 3849-3859
DOI: 10.1021/acs.analchem.5c06080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 29.01.2026. Verfasst von Wenlong Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Sensor Technology and Biomedical Instrument, School of Biomedical Engineering, Shenzhen Campus of Sun Yat-Sen …. Hauptthemen laut MEDLINE: Alzheimer Disease, MicroRNAs, tau Proteins, CRISPR-Cas Systems. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
Blood-based biomarkers present a noninvasive approach for detecting and assessing Alzheimer's disease (AD) pathophysiology, always by using sophisticated instrumentation for accurate detection. Here, we introduce CRISPR-AD, a CRISPR/Cas-based digital assay designed for the combined detection of protein and microRNA in blood. This method achieves a limit of detection (LOD) as low as 60 fg/mL for phosphorylated tau217 (p-tau217) and 0.5 fM for microRNA-34a-5p (miRNA34a), enabling successful detection in both AD patients and healthy individuals. We find that the combined use of these biomarkers improves the ability to distinguish between AD patients and healthy participants, particularly in individuals with mild cognitive impairment (MCI). Additionally, we have developed a portable device that integrates a smartphone as an imaging system for point-of-care testing (POCT), offering the potential for early stage AD screening. This study represents the first effort to evaluate the combined detection of blood protein and microRNA biomarkers for AD, underscoring the potential of multiple biomarker combinations for more accurate AD diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Sensor Technology and Biomedical Instrument, School of Biomedical Engineering, Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
- Department of Medical Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Guangdong Provincial Cl…
- Medicine School, The Chinese University of Hong Kong, Shenzhen 518172, China.
ORCID-Profile: Haofan Yin, Chenzhong Li, Cheng Jiang, Jianhua Zhou, Jiasi Wang
Förderung
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Program
- Shenzhen Medical Research Fund
- Shenzhen Peacock Team
- Pengcheng Peacok Research Fund
Zitieren
APA
Guo, W., Cheng, Y., Yin, H., Li, S., Wan, Y., Li, C., Jiang, C., Zhou, J., Yuan, X., & Wang, J. (2026). CRISPR-AD: Combinational Detection of Blood Protein and miRNA with Digital CRISPR-Based Assay Enable to Improve the Diagnostic Performance of Alzheimer’s Disease. Analytical Chemistry, 98(5), 3849-3859. https://doi.org/10.1021/acs.analchem.5c06080
Vancouver
Guo W, Cheng Y, Yin H, Li S, Wan Y, Li C, et al. CRISPR-AD: Combinational Detection of Blood Protein and miRNA with Digital CRISPR-Based Assay Enable to Improve the Diagnostic Performance of Alzheimer’s Disease. Analytical Chemistry. 2026;98(5):3849-3859. doi:10.1021/acs.analchem.5c06080
BibTeX
@article{Guo2026,
author = {Guo, Wenlong and Cheng, Yingjie and Yin, Haofan and Li, Sheng and Wan, Yunzhu and Li, Chenzhong and Jiang, Cheng and Zhou, Jianhua and Yuan, Xiaopeng and Wang, Jiasi},
title = {CRISPR-AD: Combinational Detection of Blood Protein and miRNA with Digital CRISPR-Based Assay Enable to Improve the Diagnostic Performance of Alzheimer’s Disease},
journal = {Analytical Chemistry},
year = {2026},
volume = {98},
number = {5},
pages = {3849--3859},
doi = {10.1021/acs.analchem.5c06080}
}
EUVIMED